A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Active:	Yes
Cancer Type:	Lung Cancer Unknown Primary	NCT ID:	NCT06667908
Trial Phases:	Phase II	Protocol IDs:	90301900NSC2001 (primary) NCI-2024-09803 2024-518276-32-00 90301900NSC2001
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Johnson & Johnson Enterprise Innovation Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06667908

Summary

The purpose of this study is to determine whether JNJ-90301900 added to concurrent
platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by
consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is
percentage of participants whose best response is complete response or partial response
during the study) in participants with locally advanced and unresectable stage III
non-small cell lung cancer.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.